Get the Stockscreener App
917.63
0.03%
-0.30
After Hours:
917.63
Argen X Se Adr stock is traded at $917.63, with a volume of 268.70K.
It is down -0.03% in the last 24 hours and up +12.27% over the past month.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
See More
Previous Close:
$917.93
Open:
$923.81
24h Volume:
268.70K
Relative Volume:
0.74
Market Cap:
$56.50B
Revenue:
$3.06B
Net Income/Loss:
$1.28B
P/E Ratio:
46.65
EPS:
19.6719
Net Cash Flow:
$447.35M
1W Performance:
+0.33%
1M Performance:
+12.27%
6M Performance:
+56.16%
1Y Performance:
+51.13%
1-Day Range:
$915.36
$929.00
1-Week Range:
$897.50
$932.29
52-Week Range:
$510.06
$934.13
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-15-25 | Resumed | Truist | Buy |
| Sep-11-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-08-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-13-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-17-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-12-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Strong Buy |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
ClearBridge International Growth ADR ESG Portfolios Q3 2025 Commentary - Seeking Alpha
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Oppenheimer raises argenx stock price target to $1,040 on higher Vyvgart sales By Investing.com - Investing.com South Africa
Oppenheimer raises argenx stock price target to $1,040 on higher Vyvgart sales - Investing.com India
Quant Ratings Updated on 141 Stocks - InvestorPlace
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Argenx stock reaches all-time high at 915.55 USD By Investing.com - Investing.com Nigeria
Argenx stock reaches all-time high at 915.55 USD - Investing.com
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx NV ADR stock hits all-time high of 855.68 USD - Investing.com Nigeria
Denali Therapeutics Announces Board and Executive Leadership Updates - GlobeNewswire Inc.
Argenx NV ADR stock hits all-time high of 855.68 USD By Investing.com - Investing.com South Africa
Janus Henderson Global Life Sciences Fund Q3 2025 Commentary - Seeking Alpha
argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada - Barchart.com
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View - Finviz
Piper Sandler raises argenx stock price target to $930 on strong Vyvgart sales By Investing.com - Investing.com South Africa
Piper Sandler raises argenx stock price target to $930 on strong Vyvgart sales - Investing.com
Vyvgart Fuels Strong Growth for Argenx and Supports Developing Pipeline - Morningstar
argenx SE stock price target raised to $1,146 from $800 at TD Cowen By Investing.com - Investing.com South Africa
argenx SE stock price target raised to $1,146 from $800 at TD Cowen - Investing.com India
argenx ADR earnings beat by $0.74, revenue topped estimates - Investing.com Canada
Argenx rises after Q3 earnings beat on strong sales growth By Investing.com - Investing.com South Africa
Argenx rises after Q3 earnings beat on strong sales growth - Investing.com India
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update - Sahm
Baron Health Care Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
Milei's Landslide Election Victory Sends Argentina Stocks Soaring: 5 Names To Watch - Sahm
Grupo Galicia Stock Skyrockets as Milei’s Victory Fuels Argentina’s Bank Rally – What’s Next for GGAL? - ts2.tech
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Sahm
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
Argx stock hits all-time high at 821.97 USD By Investing.com - Investing.com Philippines
Argx stock hits all-time high at 821.97 USD - Investing.com India
TD Cowen Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
argenx stock price target maintained at $800 by TD Cowen on strong Vyvgart uptake - Investing.com
Argenx Se (ARGX) Gets a Buy from Evercore ISI - The Globe and Mail
Assessing argenx: Insights From 12 Financial Analysts - Sahm
RBC Capital Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
Argenx SE Sponsored ADR (ARGX) Stock Forecast & Price Targets: Today, Tomorrow, Next Week - Traders Union
Stocks Showing Improved Relative Strength: Zai Lab ADR - inkl
Argenx NV stock hits all-time high at 803.95 USD By Investing.com - Investing.com South Africa
Argenx NV stock hits all-time high at 803.95 USD - Investing.com
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes - 富途牛牛
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.56%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):